Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
NIH seeks mechanistic research on how blockbuster incretin drugs affect cancer risk—a critical gap as these agents become mainstream for diabetes and weight loss.
Report stale or inaccurate summary
What this is
The NIH is seeking talented scientists to investigate the biological mechanisms linking incretin mimetics—increasingly used for diabetes and obesity—to changes in cancer risk. Current evidence suggests these agents may increase risk for some obesity-related cancers while protecting against others, but the underlying mechanisms remain unclear. This funding prioritizes mechanistic research over short-term endpoints like weight loss, and welcomes both preclinical laboratory work and patient-based clinical trials. The announcement runs through January 2027 and is open to a broad range of eligible organizations including universities, nonprofits, small businesses, and government entities.
Who can apply
Broad eligibility including universities (public and private), nonprofits with or without 501(c)(3) status, small businesses, state and local governments, tribal governments, and for-profit organizations. No geographic restriction; domestic U.S. applicants typical for NIH R01 awards.
Eligible applicant types
- Public housing authorities/Indian housing authorities
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- State governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Special district governments
- Native American tribal governments (Federally recognized)
- County governments
- Private institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Small businesses
- For profit organizations other than small businesses
- Independent school districts
- City or township governments
- Public and State controlled institutions of higher education
Full description — from the agency
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Topics: incretin mimetics · glp-1 receptor agonists · cancer risk mechanism · obesity-related cancers · clinical trial research · preclinical drug mechanism · gip-1 agents
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.